Richter W O, Jacob B G, Schwandt P
Department of Medicine II, University of Munich, Germany.
Int J Tissue React. 1991;13(2):107-10.
The effects of the HMG-CoA reductase inhibitors lovastatin and pravastatin were studied over 4 months on serum lipids and lipoproteins in 35 patients with severe primary hypercholesterolaemia. In 17 patients 20 mg of lovastatin/day lowered the total cholesterol level by 18% (baseline 373 mg/dl) and LDL cholesterol by 20% (baseline 300 mg/dl). The corresponding data for 40 and 80 mg of lovastatin/day were respectively -23% and -29% for total cholesterol, and -30% and -36% for LDL cholesterol. Pravastatin at 20 mg/day lowered the total cholesterol in 18 patients by 20% (baseline 373 mg/dl) and LDL cholesterol by 24% (baseline 307 mg/dl). The corresponding data for 40 mg of pravastatin per day were 24% for total cholesterol and 30% for LDL cholesterol. So the effects of both HMG-CoA reductase inhibitors on total and LDL cholesterol are comparable. HDL (high-density lipoprotein) cholesterol was increased by lovastatin, whereas pravastatin showed no influence on HDL cholesterol. The reduction of serum triglycerides, VLDL triglycerides and VLDL cholesterol was more pronounced under treatment with lovastatin than under pravastatin.
对35例重度原发性高胆固醇血症患者进行了为期4个月的研究，观察了HMG-CoA还原酶抑制剂洛伐他汀和普伐他汀对血脂和脂蛋白的影响。17例患者每天服用20mg洛伐他汀，总胆固醇水平降低了18%（基线水平为373mg/dl），低密度脂蛋白胆固醇降低了20%（基线水平为300mg/dl）。每天服用40mg和80mg洛伐他汀时，总胆固醇的相应降低幅度分别为-23%和-29%，低密度脂蛋白胆固醇的相应降低幅度分别为-30%和-36%。每天服用20mg普伐他汀使18例患者的总胆固醇降低了20%（基线水平为373mg/dl），低密度脂蛋白胆固醇降低了24%（基线水平为307mg/dl）。每天服用40mg普伐他汀时，总胆固醇降低24%，低密度脂蛋白胆固醇降低30%。因此，两种HMG-CoA还原酶抑制剂对总胆固醇和低密度脂蛋白胆固醇的作用相当。洛伐他汀可使高密度脂蛋白（HDL）胆固醇升高，而普伐他汀对HDL胆固醇无影响。与普伐他汀相比，洛伐他汀治疗下血清甘油三酯、极低密度脂蛋白甘油三酯和极低密度脂蛋白胆固醇的降低更为明显。
